Solana (HSDT)
Market Price (4/13/2026): $1.88 | Market Cap: $82.2 MilSector: Financials | Industry: Asset Management & Custody Banks
Solana (HSDT)
Market Price (4/13/2026): $1.88Market Cap: $82.2 MilSector: FinancialsIndustry: Asset Management & Custody Banks
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 1057% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -58% Megatrend and thematic driversMegatrends include Crypto & Blockchain, Fintech & Digital Payments, and Digital & Alternative Assets. Themes include Blockchain Enterprise Solutions, Show more. | Weak multi-year price returns2Y Excs Rtn is -131%, 3Y Excs Rtn is -166% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -351% Expensive valuation multiplesP/SPrice/Sales ratio is 14x Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 154% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -274%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -274% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -54% High stock price volatilityVol 12M is 4630% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 1057% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -58% |
| Megatrend and thematic driversMegatrends include Crypto & Blockchain, Fintech & Digital Payments, and Digital & Alternative Assets. Themes include Blockchain Enterprise Solutions, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -131%, 3Y Excs Rtn is -166% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -351% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 14x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 154% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -274%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -274% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -54% |
| High stock price volatilityVol 12M is 4630% |
Qualitative Assessment
AI Analysis | Feedback
1. Solana Company (HSDT) experienced significant pressure from a broader cryptocurrency market downturn and prevailing macroeconomic headwinds. The general crypto market shifted to "terrible sentiment" in early 2026, transitioning from aggressive growth to "cautious preservation," which disproportionately affected high-beta assets like Solana (SOL), leading to accelerated capital outflows. This "risk-off sentiment" was amplified by global macroeconomic factors such as the US-Iran conflict and oil prices surging past $94 a barrel in March 2026, compelling investors to move away from speculative assets towards "safe-haven" alternatives. Bitcoin's concurrent pullback also created a cascading effect across altcoins, intensifying Solana's volatility.
2. Regulatory uncertainty and specific legal challenges within the Solana ecosystem negatively impacted HSDT's valuation. The Solana ecosystem faced a series of "legal challenges targeting core entities" responsible for network development, generating significant market uncertainty that contributed to sell-offs. Beyond these specific lawsuits, the broader regulatory environment for digital assets remained complex in 2026. Increased regulatory scrutiny, partly due to the growing presence of institutional products like Solana ETFs, introduced short-term price suppression as the market anticipated new compliance standards and potential restrictive rulings.
Show more
Stock Movement Drivers
Fundamental Drivers
The -34.6% change in HSDT stock from 12/31/2025 to 4/12/2026 was primarily driven by a -75.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.89 | 1.89 | -34.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 6 | 539.4% |
| P/S Multiple | 32.9 | 13.7 | -58.3% |
| Shares Outstanding (Mil) | 11 | 44 | -75.5% |
| Cumulative Contribution | -34.6% |
Market Drivers
12/31/2025 to 4/12/2026| Return | Correlation | |
|---|---|---|
| HSDT | -34.6% | |
| Market (SPY) | -5.4% | 44.3% |
| Sector (XLF) | -7.3% | 24.4% |
Fundamental Drivers
The -87.3% change in HSDT stock from 9/30/2025 to 4/12/2026 was primarily driven by a -99.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.89 | 1.89 | -87.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 6 | 1939.7% |
| P/S Multiple | 6.2 | 13.7 | 120.7% |
| Shares Outstanding (Mil) | 0 | 44 | -99.7% |
| Cumulative Contribution | -87.3% |
Market Drivers
9/30/2025 to 4/12/2026| Return | Correlation | |
|---|---|---|
| HSDT | -87.3% | |
| Market (SPY) | -2.9% | 40.5% |
| Sector (XLF) | -5.4% | 23.1% |
Fundamental Drivers
The -99.4% change in HSDT stock from 3/31/2025 to 4/12/2026 was primarily driven by a -100.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312025 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 300.75 | 1.89 | -99.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 6 | 1057.1% |
| P/S Multiple | 2.9 | 13.7 | 379.0% |
| Shares Outstanding (Mil) | 0 | 44 | -100.0% |
| Cumulative Contribution | -99.4% |
Market Drivers
3/31/2025 to 4/12/2026| Return | Correlation | |
|---|---|---|
| HSDT | -99.4% | |
| Market (SPY) | 16.3% | 0.1% |
| Sector (XLF) | 3.0% | 3.1% |
Fundamental Drivers
The -100.0% change in HSDT stock from 3/31/2023 to 4/12/2026 was primarily driven by a -100.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312023 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 9555.00 | 1.89 | -100.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 6 | 664.5% |
| P/S Multiple | 9.1 | 13.7 | 50.5% |
| Shares Outstanding (Mil) | 0 | 44 | -100.0% |
| Cumulative Contribution | -100.0% |
Market Drivers
3/31/2023 to 4/12/2026| Return | Correlation | |
|---|---|---|
| HSDT | -100.0% | |
| Market (SPY) | 63.3% | 0.5% |
| Sector (XLF) | 64.9% | 2.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HSDT Return | -61% | -94% | -48% | -92% | -99% | -35% | -100% |
| Peers Return | 66% | -75% | 312% | 38% | -5% | -2% | 125% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| HSDT Win Rate | 33% | 25% | 42% | 25% | 33% | 25% | |
| Peers Win Rate | 50% | 32% | 68% | 52% | 60% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HSDT Max Drawdown | -61% | -96% | -62% | -95% | -100% | -41% | |
| Peers Max Drawdown | -14% | -78% | -8% | -29% | -37% | -23% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: COIN, RIOT, MARA, PYPL, NVDA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)
How Low Can It Go
| Event | HSDT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.4% | -25.4% |
| % Gain to Breakeven | 15723.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -99.3% | -33.9% |
| % Gain to Breakeven | 13468.8% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -97.2% | -19.8% |
| % Gain to Breakeven | 3418.9% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to COIN, RIOT, MARA, PYPL, NVDA
In The Past
Solana's stock fell -99.4% during the 2022 Inflation Shock from a high on 4/8/2021. A -99.4% loss requires a 15723.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Solana (HSDT)
AI Analysis | Feedback
A specialized Medtronic, but solely focused on non-invasive devices for neurological rehabilitation.
A focused Boston Scientific, creating high-tech, non-invasive solutions for gait and balance issues from neurological conditions.
AI Analysis | Feedback
- Portable Neuromodulation Stimulator (PoNS): A non-surgical medical device used to treat gait deficits from multiple sclerosis and balance deficits from mild-to-moderate traumatic brain injury, in conjunction with therapeutic exercise.
AI Analysis | Feedback
Based on the provided company description for Helius Medical Technologies, Inc. (symbol: HSDT), its product, the Portable Neuromodulation Stimulator (PoNS), is a medical device used in conjunction with supervised therapeutic exercise. The company primarily sells its device to healthcare providers and facilities rather than directly to individual consumers or a small number of large corporate entities.
The major categories of customers that Helius Medical Technologies, Inc. serves include:
- Rehabilitation Clinics and Centers: Facilities specializing in physical therapy, occupational therapy, and neurological rehabilitation, where the PoNS device is integrated into supervised exercise programs for patients with gait and balance deficits.
- Neurology Clinics: Medical practices focused on the diagnosis and treatment of neurological conditions, such as multiple sclerosis and traumatic brain injury, which may offer PoNS therapy to their patients.
- Hospitals and Integrated Healthcare Systems: Larger healthcare organizations with departments dedicated to neurology, physical medicine, and rehabilitation that can acquire and utilize the PoNS device as part of their patient treatment offerings.
AI Analysis | Feedback
nullAI Analysis | Feedback
Dane C. Andreeff, President and Chief Executive Officer
Mr. Andreeff was appointed President and Chief Executive Officer of Helius Medical Technologies, Inc. (now Solana Company) effective June 14, 2021, having previously served as Interim President and CEO since August 2020. He has been a member of the Company's Board of Directors since August 2017. Mr. Andreeff founded Maple Leaf Partners, LP, a hedge fund, in 1996, where he serves as General Partner and Portfolio Manager. The fund was seeded by Julian Robertson's Tiger Management in 2003 and at one point grew to over $2 billion in assets under management. He also holds board positions on two other healthcare companies.
Jeffrey S. Mathiesen, Chief Financial Officer, Treasurer and Secretary
Mr. Mathiesen was appointed Chief Financial Officer, Treasurer and Secretary of Helius Medical Technologies, Inc. (now Solana Company) effective June 14, 2021. He is a Certified Public Accountant (inactive) and has served in previous CFO roles for public medical technology and biopharmaceutical companies. Mr. Mathiesen has also served on various public company boards, including NeuroOne (NMTC) and Panbela (PBLA), where he was Vice Chair and Lead Independent Director since March 2020 and Director and Audit Committee Chair since 2015.
Joseph Chee, Executive Chairman
Mr. Chee was appointed Executive Chairman of the Board of Solana Company, effective September 18, 2025. He is the Founder and Chairman of Summer Capital Limited, an investment company that focuses on early growth stage companies in sectors such as fintech, blockchain infrastructure, consumption technology, and healthcare. Additionally, Mr. Chee has served as Vice Chairman of AMINA Bank AG, a FINMA-regulated cryptocurrency bank, since April 2020. He also founded Summer Healthcare Fund, L.P. and Summer Everest Ecosystem Fund, L.P., which are investment companies focused on healthcare and biotechnology, and blockchain ecosystem and financial technology, respectively. Prior to these roles, Mr. Chee held positions including Head of Investment Banking and Head of Global Capital Markets, Asia at UBS AG from 2000 to 2017.
Antonella Favit-Van Pelt, Chief Medical Officer
Dr. Favit-Van Pelt serves as the Chief Medical Officer of Solana Company. No additional background details were readily available in the provided sources.
AI Analysis | Feedback
nullAI Analysis | Feedback
- The emergence of new, more effective non-invasive neuromodulation devices or therapies from competitors that offer superior outcomes, broader indications, or less reliance on intensive adjunctive supervised therapeutic exercise.
- Significant advancements in pharmaceutical or biological treatments for multiple sclerosis and traumatic brain injury symptoms that directly address gait and balance deficits, potentially reducing or negating the need for adjunctive device-based therapies.
- Rapid evolution in rehabilitation technology, including advanced robotics, virtual reality-based systems, or AI-driven personalized therapy platforms, which could provide more comprehensive or integrated solutions for neurological rehabilitation, potentially displacing or diminishing the role of PoNS.
AI Analysis | Feedback
For Helius Medical Technologies, Inc. (symbol: HSDT), the addressable markets for its main product, the Portable Neuromodulation Stimulator (PoNS), are related to the treatment of gait deficit due to multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury.
Market for Gait Deficit Due to Multiple Sclerosis (MS)
- The global multiple sclerosis treatment market was valued at approximately USD 28.28 billion in 2024 and is projected to grow to about USD 39.39 billion by 2033. Another estimate places the global market at USD 23.64 billion in 2023, expected to reach USD 43.40 billion by 2032.
- In the seven major markets (7MM: United States, EU4, United Kingdom, and Japan), the Multiple Sclerosis market was valued at approximately USD 20 billion in 2024.
- The U.S. Multiple Sclerosis market alone was approximately USD 16 billion in 2024.
- Globally, an estimated 2.8 million people were affected by MS in 2020.
- Difficulty walking is a very common mobility issue in multiple sclerosis, affecting 50-80% of people with the disease. Between 50% and 80% of individuals with MS experience balance and gait dysfunction.
Market for Balance Deficit Due to Mild-to-Moderate Traumatic Brain Injury (mmTBI)
- The global traumatic brain injury (TBI) treatment market was valued at USD 3.67 billion in 2024 and is expected to reach USD 6.13 billion by 2032. Another projection indicates the global TBI market was valued at USD 2.5 billion in 2024 and is expected to reach US$ 4.7 billion by 2033.
- For the 7MM (United States, EU4, United Kingdom, and Japan), the TBI market was approximately USD 1.3 billion in 2024. The U.S. constituted 85% of this 7MM market in 2024.
- Mild traumatic brain injury affects an estimated 55.9 million people worldwide each year.
- Difficulties in maintaining balance persist for months or years after a mild traumatic brain injury in over 30% of patients. Up to 65% of individuals with TBI experience balance problems.
AI Analysis | Feedback
nullAI Analysis | Feedback
Capital Allocation Decisions for Helius Medical Technologies, Inc. (HSDT) (Last 3-5 Years)
Share Repurchases
- On November 3, 2025, Helius Medical Technologies' Board authorized a stock repurchase program for the purchase of up to $100 million of its outstanding common stock.
Share Issuance
- In September 2025, Helius Medical Technologies completed an oversubscribed private investment in public equity (PIPE) offering, generating over $500 million in gross proceeds, with the potential to reach over $1.25 billion including warrant exercises.
- The company raised $9.1 million in June 2025 through a public offering of common stock and warrants.
- Helius executed a 1-for-50 reverse stock split effective June 30, 2025, which reduced the number of outstanding shares from approximately 33.8 million to 0.7 million.
Inbound Investments
- The September 2025 PIPE offering resulted in over $500 million in funding from institutional and crypto-native investors, including Pantera Capital and Summer Capital, with the potential for over $1.25 billion through warrant exercises. This investment was specifically aimed at transforming the company into a Solana (SOL) digital asset treasury vehicle.
Outbound Investments
- Helius Medical Technologies made a strategic pivot in September 2025 to become a Solana (SOL) digital asset treasury vehicle.
- The net proceeds from the September 2025 offering are intended for the acquisition of SOL, Solana's native cryptocurrency, to serve as the company's primary treasury reserve asset.
- As of March 2026, Helius Medical Technologies held 2,300,000 SOL valued at $204.1 million.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to HSDT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | HBAN | Huntington Bancshares | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 03312026 | NP | Neptune Insurance | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 03272026 | JKHY | Jack Henry & Associates | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 3.1% | 3.1% | 0.0% |
| 03202026 | MKTX | MarketAxess | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -5.2% | -5.2% | -5.7% |
| 03202026 | RYAN | Ryan Specialty | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | -2.7% | -2.7% | -8.5% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 30.92 |
| Mkt Cap | 24.0 |
| Rev LTM | 4,044 |
| Op Inc LTM | 718 |
| FCF LTM | 1,205 |
| FCF 3Y Avg | 1,017 |
| CFO LTM | 1,205 |
| CFO 3Y Avg | 1,028 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 51.8% |
| Rev Chg 3Y Avg | 70.6% |
| Rev Chg Q | 5.5% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Mgn LTM | -16.9% |
| Op Mgn 3Y Avg | -23.0% |
| QoQ Delta Op Mgn LTM | -1.0% |
| CFO/Rev LTM | -34.6% |
| CFO/Rev 3Y Avg | -14.2% |
| FCF/Rev LTM | -58.3% |
| FCF/Rev 3Y Avg | -51.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 24.0 |
| P/S | 7.6 |
| P/EBIT | 2.1 |
| P/E | 3.0 |
| P/CFO | 1.1 |
| Total Yield | -4.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -9.0% |
| D/E | 0.2 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.6% |
| 3M Rtn | -14.0% |
| 6M Rtn | -41.9% |
| 12M Rtn | -14.0% |
| 3Y Rtn | 2.9% |
| 1M Excs Rtn | -0.3% |
| 3M Excs Rtn | -13.9% |
| 6M Excs Rtn | -47.5% |
| 12M Excs Rtn | -36.1% |
| 3Y Excs Rtn | -23.4% |
Price Behavior
| Market Price | $1.89 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 07/07/2014 | |
| Distance from 52W High | -99.2% | |
| 50 Days | 200 Days | |
| DMA Price | $2.07 | $5.81 |
| DMA Trend | down | down |
| Distance from DMA | -8.9% | -67.5% |
| 3M | 1YR | |
| Volatility | 109.8% | 4,676.5% |
| Downside Capture | 2.69 | 0.61 |
| Upside Capture | 494.23 | -495.59 |
| Correlation (SPY) | 42.4% | -0.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.34 | 4.66 | 3.78 | 4.20 | 0.14 | 0.81 |
| Up Beta | -4.72 | 4.46 | 2.65 | 2.21 | 0.51 | 1.11 |
| Down Beta | 2.54 | 1.06 | 2.18 | 3.15 | 34.20 | 18.65 |
| Up Capture | 1223% | 837% | 624% | 338% | -62% | -7% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 9 | 14 | 24 | 49 | 99 | 306 |
| Down Capture | 309% | 392% | 328% | 293% | 115% | 112% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 13 | 28 | 37 | 75 | 149 | 429 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HSDT | |
|---|---|---|---|---|
| HSDT | -99.1% | 4,648.3% | 0.92 | - |
| Sector ETF (XLF) | 16.9% | 17.3% | 0.74 | 3.2% |
| Equity (SPY) | 31.2% | 17.3% | 1.47 | -0.3% |
| Gold (GLD) | 60.1% | 27.8% | 1.69 | 2.9% |
| Commodities (DBC) | 29.8% | 16.6% | 1.58 | 3.7% |
| Real Estate (VNQ) | 21.3% | 15.2% | 1.07 | 4.4% |
| Bitcoin (BTCUSD) | -4.3% | 43.7% | 0.02 | -2.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HSDT | |
|---|---|---|---|---|
| HSDT | -92.2% | 2,075.5% | 0.36 | - |
| Sector ETF (XLF) | 9.7% | 18.7% | 0.40 | 2.0% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 0.8% |
| Gold (GLD) | 22.1% | 17.8% | 1.02 | 2.4% |
| Commodities (DBC) | 11.8% | 18.8% | 0.52 | 1.7% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 2.1% |
| Bitcoin (BTCUSD) | 4.3% | 56.5% | 0.30 | -0.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HSDT | |
|---|---|---|---|---|
| HSDT | -85.2% | 1,642.6% | 0.28 | - |
| Sector ETF (XLF) | 12.7% | 22.2% | 0.53 | 1.5% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 0.8% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | 2.2% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 1.6% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.22 | 1.6% |
| Bitcoin (BTCUSD) | 67.6% | 66.9% | 1.07 | -0.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/31/2026 | -1.7% | 8.7% | |
| 11/18/2025 | -6.0% | -10.3% | -25.5% |
| 8/12/2024 | -4.5% | -9.7% | 1.7% |
| 3/28/2024 | -3.6% | 5.1% | -29.8% |
| 11/2/2023 | 2.2% | -13.5% | -14.2% |
| 8/10/2023 | -0.6% | -17.2% | -4.7% |
| 5/11/2023 | -12.3% | -6.5% | -0.1% |
| 1/23/2023 | 0.8% | 8.6% | -21.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 4 | 6 | 3 |
| # Negative | 13 | 11 | 13 |
| Median Positive | 6.8% | 8.6% | 3.1% |
| Median Negative | -4.9% | -11.5% | -6.2% |
| Max Positive | 11.5% | 26.2% | 40.5% |
| Max Negative | -23.7% | -28.1% | -31.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/18/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 03/25/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.